Oct. 15 - FDA panel's recommendation on silicone gel breast implants is reckless

To read Health Research Group Director Dr. Sidney Wolfe's statement on the FDA advisory panel recommendation, click here.

In testimony Oct. 14 before an FDA panel convened to address the Inamed application for approval of silicone gel breast implants, Wolfe said that because the company has submitted only three years of data from a study intended to run 10 years, the FDA cannot be reasonably assured of the implants’ safety.

To read the press release on the Oct. 14 testimony, click here.